Capital Impact Advisors LLC reduced its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) by 47.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 59,301 shares of the biopharmaceutical company’s stock after selling 53,776 shares during the period. Catalyst Pharmaceuticals comprises about 0.9% of Capital Impact Advisors LLC’s holdings, making the stock its 16th largest holding. Capital Impact Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $907,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of CPRX. FMR LLC boosted its holdings in Catalyst Pharmaceuticals by 24.2% in the second quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 822 shares during the period. Covestor Ltd boosted its holdings in Catalyst Pharmaceuticals by 768.0% in the first quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,316 shares during the period. Quantbot Technologies LP purchased a new position in Catalyst Pharmaceuticals in the first quarter valued at $62,000. KBC Group NV purchased a new position in Catalyst Pharmaceuticals in the third quarter valued at $106,000. Finally, Point72 Hong Kong Ltd boosted its holdings in Catalyst Pharmaceuticals by 63.0% in the first quarter. Point72 Hong Kong Ltd now owns 9,670 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 3,738 shares during the period. 86.66% of the stock is currently owned by hedge funds and other institutional investors.
Catalyst Pharmaceuticals Stock Performance
CPRX opened at $15.75 on Friday. The business’s 50-day simple moving average is $16.48 and its 200-day simple moving average is $15.58. Catalyst Pharmaceuticals, Inc. has a one year low of $6.15 and a one year high of $22.11. The stock has a market capitalization of $1.64 billion, a P/E ratio of 25.82 and a beta of 1.16.
Wall Street Analyst Weigh In
Catalyst Pharmaceuticals Profile
Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms.
- Get a free copy of the StockNews.com research report on Catalyst Pharmaceuticals (CPRX)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating).
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.